Pro-Pharmaceuticals (PRW) Receives Non-Compliance Notification From AMEX
More News related to PRW
- Pro-Pharmaceuticals (PRW) Anticipates Listing on Bulletin Board; Releases President and Chief Scientist
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Pro-Pharmaceuticals (PRW) Announces FDA Approves IND For Use of DAVANAT
- Pro-Pharmaceuticals (PRW) Reports Positive Phase II Data of DAVANAT in Combination with 5-fluorouracil
- Pro-Pharmaceuticals (PRW) Receives Non-Compliance Notification From AMEX
Pro-Pharmaceuticals, Inc. (Amex: PRW) received a notice from the American Stock Exchange Listing Qualifications Department that it is reviewing the Company\'s eligibility for continued listing. Specifically, the notice cited that the Company does not comply with the Amex\'s minimum $2 million stockholders\' equity and losses from continuing operations and/or net losses in two of its last three years set forth in Section 1003 (a) (i) of the Amex Company Guide. To facilitate the review, the Company has been asked to provide, on or before July 23, 2007, a specific plan and timeframe to achieve and sustain compliance with all Amex market listing requirements. The Company intends to submit a plan to regain compliance on or before the requested date.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
